Anthony V. Moorman

20.1k total citations · 4 hit papers
183 papers, 10.2k citations indexed

About

Anthony V. Moorman is a scholar working on Public Health, Environmental and Occupational Health, Hematology and Pediatrics, Perinatology and Child Health. According to data from OpenAlex, Anthony V. Moorman has authored 183 papers receiving a total of 10.2k indexed citations (citations by other indexed papers that have themselves been cited), including 153 papers in Public Health, Environmental and Occupational Health, 117 papers in Hematology and 50 papers in Pediatrics, Perinatology and Child Health. Recurrent topics in Anthony V. Moorman's work include Acute Lymphoblastic Leukemia research (153 papers), Acute Myeloid Leukemia Research (76 papers) and Chronic Myeloid Leukemia Treatments (62 papers). Anthony V. Moorman is often cited by papers focused on Acute Lymphoblastic Leukemia research (153 papers), Acute Myeloid Leukemia Research (76 papers) and Chronic Myeloid Leukemia Treatments (62 papers). Anthony V. Moorman collaborates with scholars based in United Kingdom, United States and Netherlands. Anthony V. Moorman's co-authors include Christine J. Harrison, Anthony H. Goldstone, Alan K. Burnett, Robert K. Hills, Keith Wheatley, Ajay Vora, David Grimwade, S Chatters, Helen M. Walker and Lucy Chilton and has published in prestigious journals such as Nature, Proceedings of the National Academy of Sciences and The Lancet.

In The Last Decade

Anthony V. Moorman

177 papers receiving 10.0k citations

Hit Papers

Refinement of cytogenetic classification in acute myeloid... 2006 2026 2012 2019 2010 2010 2006 2014 400 800 1.2k
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Refinement of cytogenetic classification in acute myeloid leukemia: determination of prognostic significance of rare recurring chromosomal abnormalities among 5876 younger adult patients treated in the United Kingdom Medical Research Council trials
    2010 1.3k citations David Grimwade, Robert K. Hills et al. Blood profile →
  2. Genetic variegation of clonal architecture and propagating cells in leukaemia
    2010 569 citations Frederik W. van Delft, Caroline M. Bateman et al. Nature profile →
  3. Karyotype is an independent prognostic factor in adult acute lymphoblastic leukemia (ALL): analysis of cytogenetic data from patients treated on the Medical Research Council (MRC) UKALLXII/Eastern Cooperative Oncology Group (ECOG) 2993 trial
    2006 502 citations Anthony V. Moorman, Christine J. Harrison et al. Blood profile →
  4. Addition of gemtuzumab ozogamicin to induction chemotherapy in adult patients with acute myeloid leukaemia: a meta-analysis of individual patient data from randomised controlled trials
    2014 479 citations Robert K. Hills, Sylvie Castaigné et al. The Lancet Oncology profile →

Peers

Anthony V. Moorman
David R. Head United States
Elisabeth R. van Wering Netherlands
Claudia Schoch Germany
C. Sultan France
Eva Hellström‐Lindberg Sweden
Felicetto Ferrara Italy
Rosemary E. Gale United Kingdom
Renato Bassan Italy
CH Pui United States
Mihaela Onciu United States
David R. Head United States
Anthony V. Moorman
Citations per year, relative to Anthony V. Moorman Anthony V. Moorman (= 1×) peers David R. Head

Countries citing papers authored by Anthony V. Moorman

Since Specialization
Citations

This map shows the geographic impact of Anthony V. Moorman's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Anthony V. Moorman with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Anthony V. Moorman more than expected).

Fields of papers citing papers by Anthony V. Moorman

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Anthony V. Moorman. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Anthony V. Moorman. The network helps show where Anthony V. Moorman may publish in the future.

Co-authorship network of co-authors of Anthony V. Moorman

This figure shows the co-authorship network connecting the top 25 collaborators of Anthony V. Moorman. A scholar is included among the top collaborators of Anthony V. Moorman based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Anthony V. Moorman. Anthony V. Moorman is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Scott, James N., Matthew Edwards, Xiaoling Wang, et al.. (2025). Excised DNA circles from V(D)J recombination promote relapsed leukaemia. Nature. 645(8081). 774–783.
2.
O’Connor, David, Jose Espejo Valle-Inclán, Lucía Conde, et al.. (2024). Noncoding mutations drive persistence of a founder preleukemic clone which initiates late relapse in T-ALL. Blood. 143(10). 933–937. 4 indexed citations
3.
Boeree, Aurélie, Edwin Sonneveld, Anthony V. Moorman, et al.. (2023). Targeted treatment options for paediatric B-cell precursor acute lymphoblastic leukaemia patients with constitutional or somatic chromosome 21 alterations. SHILAP Revista de lepidopterología. 3. 100140–100140. 2 indexed citations
4.
Blair, Helen J., Anthony V. Moorman, Olaf Heidenreich, et al.. (2023). Targeting WEE1 kinase as a p53-independent therapeutic strategy in high-risk and relapsed acute lymphoblastic leukemia. Cancer Cell International. 23(1). 202–202. 2 indexed citations
5.
Enshaei, Amir, Melvin Joy, Amy A. Kirkwood, et al.. (2023). A robust and validated integrated prognostic index for defining risk groups in adult acute lymphoblastic leukemia: an EWALL collaborative study. Blood Advances. 8(5). 1155–1166. 2 indexed citations
6.
O’Connor, David, Jonas Demeulemeester, Lucía Conde, et al.. (2023). The Clinicogenomic Landscape of Induction Failure in Childhood and Young Adult T-Cell Acute Lymphoblastic Leukemia. Journal of Clinical Oncology. 41(19). 3545–3556. 12 indexed citations
7.
Sinclair, Paul, Prahlad V. Raninga, Sarra Ryan, et al.. (2023). Disruption to the FOXO-PRDM1 axis resulting from deletions of chromosome 6 in acute lymphoblastic leukaemia. Leukemia. 37(3). 636–649. 4 indexed citations
8.
Taj, Mary, Anthony V. Moorman, Arnaud Petit, et al.. (2021). Prognostic value of Oncogenetic mutations in pediatric T Acute Lymphoblastic Leukemia: a comparison of UKALL2003 and FRALLE2000T protocols. Leukemia. 36(1). 263–266. 4 indexed citations
9.
Sellar, Rob S., Clare Rowntree, Ajay Vora, et al.. (2018). Relapse in teenage and young adult patients treated on a paediatric minimal residual disease stratified ALL treatment protocol is associated with a poor outcome: results from UKALL2003. British Journal of Haematology. 181(4). 515–522. 9 indexed citations
10.
Potter, Catherine, Anthony V. Moorman, Caroline L. Relton, et al.. (2018). Maternal Red Blood Cell Folate and Infant Vitamin B12 Status Influence Methylation of Genes Associated with Childhood Acute Lymphoblastic Leukemia. Molecular Nutrition & Food Research. 62(22). e1800411–e1800411. 10 indexed citations
11.
O’Connor, David, Amir Enshaei, Jack Bartram, et al.. (2017). Genotype-Specific Minimal Residual Disease Interpretation Improves Stratification in Pediatric Acute Lymphoblastic Leukemia. Journal of Clinical Oncology. 36(1). 34–43. 99 indexed citations
12.
Schwab, Claire, Sarra Ryan, Lucy Chilton, et al.. (2016). EBF1-PDGFRB fusion in pediatric B-cell precursor acute lymphoblastic leukemia (BCP-ALL): genetic profile and clinical implications. Blood. 127(18). 2214–2218. 80 indexed citations
13.
Moorman, Anthony V., Julie Irving, Amir Enshaei, et al.. (2015). Composite Index for Risk Prediction in Relapsed Childhood Acute Lymphoblastic Leukaemia. Haematologica. 100. 195–196. 3 indexed citations
14.
Russell, Lisa J., Amir Enshaei, Lisa Jones, et al.. (2014). IGH @ Translocations Are Prevalent in Teenagers and Young Adults With Acute Lymphoblastic Leukemia and Are Associated With a Poor Outcome. Journal of Clinical Oncology. 32(14). 1453–1462. 57 indexed citations
15.
Hills, Robert K., Sylvie Castaigné, Frederick R. Appelbaum, et al.. (2014). Addition of gemtuzumab ozogamicin to induction chemotherapy in adult patients with acute myeloid leukaemia: a meta-analysis of individual patient data from randomised controlled trials. The Lancet Oncology. 15(9). 986–996. 479 indexed citations breakdown →
16.
Grimwade, David, Robert K. Hills, Anthony V. Moorman, et al.. (2009). REFINEMENT OF CYTOGENETIC CLASSIFICATION IN AML: DETERMINATION OF PROGNOSTIC SIGNIFICANCE OF RARE RECURRING CHROMOSOMAL ABNORMALITIES AMONGST 5635 YOUNGER ADULTS TREATED IN THE UK MRC TRIALS. Haematologica. 94. 217–217. 5 indexed citations
17.
18.
19.
20.
Barber, Kerry E., Christine J. Harrison, Adam Stewart, et al.. (2007). Molecular cytogenetic characterization of TCF3 (E2A)/19p13.3 rearrangements in B‐cell precursor acute lymphoblastic leukemia. Genes Chromosomes and Cancer. 46(5). 478–486. 45 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by David R. Head Breakdown of academic impact, for papers by Elisabeth R. van Wering Breakdown of academic impact, for papers by Claudia Schoch Breakdown of academic impact, for papers by C. Sultan Breakdown of academic impact, for papers by Eva Hellström‐Lindberg Breakdown of academic impact, for papers by Felicetto Ferrara Breakdown of academic impact, for papers by Rosemary E. Gale Breakdown of academic impact, for papers by Renato Bassan Breakdown of academic impact, for papers by CH Pui Breakdown of academic impact, for papers by Mihaela Onciu
Rankless by CCL
2026